Literature DB >> 28932964

Treatment Strategies for the Opioid-Dependent Patient.

Shweta Teckchandani1, Meredith Barad2.   

Abstract

PURPOSE OF REVIEW: This review is intended to help the headache physician think through and plan for management issues concerning the use of opioids. We ask the headache physician to consider if there are instances where prescribing or continuing prescriptions of opiates is plausible, and if so, how can the physician proceed as safely as possible. Our goal is to start a conversation regarding the inevitable encounter with a patient on opiates or requesting opiates. RECENT
FINDINGS: The use of opiates in our society has reached a crisis in staggering death and addiction rates. Recent guideline published by the CDC can assist us in developing an algorithmic approach towards opiate use. Recent advances in addiction medicine can also assist us in protecting our patients. Every headache physician will undoubtedly encounter patients on opiates. There still are appropriate reasons to treat patients with opiates. Every headache physician may need to prescribe opiates and they may be indicated. It is important to learn the correct way to approach, manage, and treat patients on opiates.

Entities:  

Keywords:  Addiction; Opiate abuse; Opioid management; Prescribing opiates

Mesh:

Substances:

Year:  2017        PMID: 28932964     DOI: 10.1007/s11916-017-0644-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  41 in total

1.  Current Progress in Opioid Treatment.

Authors:  George E Woody
Journal:  Am J Psychiatry       Date:  2017-05-01       Impact factor: 18.112

2.  Opioid use and dependence among persons with migraine: results of the AMPP study.

Authors:  Dawn C Buse; Starr H Pearlman; Michael L Reed; Daniel Serrano; Daisy S Ng-Mak; Richard B Lipton
Journal:  Headache       Date:  2012-01       Impact factor: 5.887

3.  Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.

Authors:  Paolo Mannelli; Li-Tzy Wu; Kathleen S Peindl; Marvin S Swartz; George E Woody
Journal:  Drug Alcohol Depend       Date:  2014-02-15       Impact factor: 4.492

4.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.

Authors:  Lynn R Webster; Rebecca M Webster
Journal:  Pain Med       Date:  2005 Nov-Dec       Impact factor: 3.750

5.  Increases in Drug and Opioid-Involved Overdose Deaths - United States, 2010-2015.

Authors:  Rose A Rudd; Puja Seth; Felicita David; Lawrence Scholl
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2016-12-30       Impact factor: 17.586

6.  Prescription opioids for back pain and use of medications for erectile dysfunction.

Authors:  Richard A Deyo; David H M Smith; Eric S Johnson; Carrie J Tillotson; Marilee Donovan; Xiuhai Yang; Amanda Petrik; Benjamin J Morasco; Steven K Dobscha
Journal:  Spine (Phila Pa 1976)       Date:  2013-05-15       Impact factor: 3.468

7.  Reducing the Risks of Relief--The CDC Opioid-Prescribing Guideline.

Authors:  Thomas R Frieden; Debra Houry
Journal:  N Engl J Med       Date:  2016-03-15       Impact factor: 91.245

8.  Treatment retention among patients randomized to buprenorphine/naloxone compared to methadone in a multi-site trial.

Authors:  Yih-Ing Hser; Andrew J Saxon; David Huang; Al Hasson; Christie Thomas; Maureen Hillhouse; Petra Jacobs; Cheryl Teruya; Paul McLaughlin; Katharina Wiest; Allan Cohen; Walter Ling
Journal:  Addiction       Date:  2013-10-09       Impact factor: 6.526

9.  Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders.

Authors:  Constance M Weisner; Cynthia I Campbell; Thomas G Ray; Kathleen Saunders; Joseph O Merrill; Caleb Banta-Green; Mark D Sullivan; Michael J Silverberg; Jennifer R Mertens; Denise Boudreau; Michael Von Korff
Journal:  Pain       Date:  2009-07-05       Impact factor: 6.961

10.  Differential Effects of Oxycodone, Hydrocodone, and Morphine on Activation Levels of Signaling Molecules.

Authors:  Michael A Emery; M L Shawn Bates; Paul J Wellman; Shoshana Eitan
Journal:  Pain Med       Date:  2015-09-09       Impact factor: 3.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.